A simple two-gene prognostic model for adenocarcinoma of the lung

Journal of Thoracic and Cardiovascular Surgery

Volumn 135, Issue 3, 2008, Pages 627-634

  Reed, Carolyn E ^a   Graham, Amanda ^a   Hoda, Rana S ^a   Khoor, Andras ^c   Garrett Mayer, Elizabeth ^b   Wallace, Michael B ^c   Mitas, Michael ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; CADHERINS; CALMODULIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; KERATIN-19; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 40149103758     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.10.058     Document Type: Article

References (28)

1. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 11 (1997) 1710-1717
2. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
3. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352 (2005) 2589-2597
4. Strauss G., Herndon J., Maddaus M., Johnstone D.W., Johnson E.A., Watson D.M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol 24 (2006) 365s
5. Pignon J., Tribodet H., Scagliotti G., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. Proc Am Soc Clin Oncol 24 (2006) 366s
6. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 355 (2006) 570-580
7. Bertucci F., Finetti P., Cervera N., Maraninchi D., Viens P., and Birnbaum D. Gene expression profiling and clinical outcome in breast cancer. OMICS 10 (2006) 429-443
8. Mikhitarian K., Gillanders W.E., Almeida J.S., Herbert-Martin R., Varela J.C., Metcalf J.S., et al. An innovative microarray strategy identifies informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res 11 (2005) C-704
9. Sprecht K., Richter T., Mueller U., Walch A., Werner M., and Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158 (2001) 419-429
10. Segal E., Friedman N., Koller D., and Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet 36 (2004) 1090-1098
11. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 (2002) 1037-1057
12. D'Amico T.A., Massey M., Herndon J.E., Moore M.-B., and Harpole D.H. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
13. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Taesher Z., Pacyna-Gengelbach M., et al. Diversity of gene expression in adenocarcinoma of lung. Proc Natl Acad Sci U S A 98 (2001) 13784-13789
14. Chen C., Gharib T.G., Huang C.-C., Kuick R., Thomas D.G., Shedden K.A., et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 100 (2003) 13537-13542
15. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveal distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98 (2001) 13790-13795
16. Wigle D.A., Jurisica I., Radulovich N., Pintilie M., Rossant J., Liu N., et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62 (2002) 3005-3008
17. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 (2006) 189-198
18. Endoh H., Tomida S., Yatabe Y., Konishi H., Osada H., Tajima K., et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 22 (2004) 811-819
19. Gordon G.J., Jensen R.V., Hsiao L.-L., Gullans S.R., Blumenstock J.E., Ramaswamy S., et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 (2002) 4963-4967
20. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., et al. A five gene signature and clinical outcome in non-small cell lung cancer. N Engl J Med 356 (2007) 11-20
21. Kikuchi T., and Carbone D.P. Proteomic analysis in lung cancer: challenges and opportunities. Respirology 12 (2007) 22-28
22. Gordon G.J., Richards W.G., Sugarbaker D.J., Jaklitsch M.T., and Bueno R. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 12 (2003) 905-910
23. Ohmachi T., Taneka F., Mimori K., Inoue H., Yanaga K., and Mori M. Clinical significance of TROP2 in colorectal cancer. Clin Cancer Res 12 (2006) 3057-3063
24. Patel I.S., Madan P., Getsios S., Bertrand M.M., and MacCalman C.O. Cadherin switching in ovarian cancer progression. Int J Cancer 106 (2003) 172-177
25. Zou M., Famulski K.S., Parhour R.S., Baitei E., Al-Mohann F.A., Farid N.R., et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts 1) gene over expression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 61646-61654
26. Taniuchi K., Nakagawa H., Hosokawa M., Nakamura T., Eguchi H., Ohigashi H., et al. Over expressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65 (2005) 3092-3099
27. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects of patients with nonmalignant diseases. Clin Cancer Res 10 (2004) 6897-6904
28. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 (2004) 781-791